Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Multiple Myeloma
Multiple Myeloma
Docs are excited about CAR-T, BTK drugs, survey finds. How can pharma best promote them?
Fierce Pharma
Tue, 01/7/20 - 11:11 pm
physicians
oncologists
Multiple Myeloma
CAR-T
Upcoming events – Karyopharm's myeloma expansion and Pfizer's biz dev news
EP Vantage
Sun, 01/5/20 - 07:11 pm
Karyopharm
Xpovio
Multiple Myeloma
Pfizer
Akcea
Ionis Pharmaceuticals
AKCEA-ANGPTL3-Lrx
GSK poised to leap back into the oncology market with more positive belantamab mafodotin results — but BCMA rivals are swarming in behind
Endpoints
Mon, 12/16/19 - 10:39 pm
GSK
Multiple Myeloma
belantamab mafodotin
clinical trials
ASH: J&J's Darzalex cuts death risk by 40% in new myeloma patients
Fierce Pharma
Mon, 12/9/19 - 11:24 pm
JNJ
Darzalex
Multiple Myeloma
ASH2019
ASH: Amgen's BiTE stalls multiple myeloma relapse in mice in combo with BMS' Revlimid
Fierce Biotech
Mon, 12/9/19 - 09:53 am
Amgen
ASH2019
bispecific antibodies
AMG 701
Multiple Myeloma
Myeloma cell therapies, now in pharma hands, move into spotlight
Biopharma Dive
Sat, 12/7/19 - 11:47 pm
ASH2019
cell therapies
Multiple Myeloma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
AbbVie signs potential $2.4bn cancer immunotherapy deal with Harpoon
Pharmaforum
Thu, 11/21/19 - 10:39 am
AbbVie
Harpoon Therapeutics
R&D
BCMA
Multiple Myeloma
Takeda scores a win for Ninlaro as it aims to pioneer 'switch' maintenance in multiple myeloma
Fierce Pharma
Fri, 11/8/19 - 10:57 am
Takeda
Ninlaro
Multiple Myeloma
clinical trials
J&J's Darzalex makes FDA history with another myeloma nod in new patients
Fierce Pharma
Fri, 09/27/19 - 09:56 am
JNJ
Darzalex
FDA
Multiple Myeloma
Amgen's Kyprolis, J&J's Darzalex team up on myeloma survival win
Fierce Pharma
Mon, 09/16/19 - 09:25 am
Amgen
Kyprolis
JNJ
Darzalex
Multiple Myeloma
Italian gene therapy player draws new investor from China for its answer to CAR-T relapses
Endpoints
Tue, 09/10/19 - 11:37 pm
gene therapy
Genenta Science
clinical trials
glioblastoma
Multiple Myeloma
CAR-T
GSK's anti-BCMA drug hits goal in pivotal multiple myeloma test
Fierce Biotech
Fri, 08/23/19 - 10:14 am
GSK
anti-BCMA
Multiple Myeloma
belantamab mafodotin
Karyopharm’s Xpovio nabs myeloma nod despite checkered past. But 5th line?
Fierce Pharma
Mon, 07/8/19 - 08:07 pm
Karyopharm
FDA
Multiple Myeloma
Xpovio
Selinexor
After negative panel vote, FDA approves Karyopharm's multiple myeloma drug
BioCentury
Fri, 07/5/19 - 01:36 pm
Karyopharma
Xpovio
Selinexor
FDA
Multiple Myeloma
FDA quickly approves J&J’s Darzalex in multiple myeloma
Pharmaforum
Fri, 06/28/19 - 12:32 pm
JNJ
Janssen
FDA
Darzalex
Multiple Myeloma
FDA lifts hold on AbbVie multiple myeloma study
Biopharma Dive
Tue, 06/25/19 - 07:19 pm
FDA
AbbVie
Venclexta
clinical trials
Multiple Myeloma
AbbVie gets a green light to resume recruiting patients for one myeloma study — but Venclexta remains under a cloud
Endpoints
Mon, 06/24/19 - 10:54 am
AbbVie
Venclexta
Multiple Myeloma
FDA
clinical trials
J&J bags $150M option on Genmab's Darzalex successor
Fierce Biotech
Tue, 06/11/19 - 09:34 am
Genmab
JNJ
Darzalex
Multiple Myeloma
drug development
Amgen Cancer Treatment Candidate Had 'Adverse Events' in Almost Half of Patients
TheStreet.com
Wed, 06/5/19 - 09:35 am
Amgen
AMG 420
Multiple Myeloma
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
BioCentury
Mon, 06/3/19 - 08:17 pm
ASCO 2019
Celgene
Multiple Myeloma
Five Prime Therapeutics
Iovance
Merck
Moderna Therapeutics
Eli Lilly
ICR
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »